Changing the Way We Treat Cancer with CYT-6091: A Model Cancer Nanomedicine
	Lawrence Tamarkin President & CEO CytImmune Sciences, Inc.

Lawrence Tamarkin, Ph.D. - CEO and Founder, CytImmune Sciences, Inc. Dr. Tamarkin has lead CytImmune from its founding in 1988 as a diagnostic company to its current focus on cancer therapeutics. Dr. Tamarkin is the co-inventor of the colloidal gold-based, tumor-targeted nanomedicine platform technology, which is covered in 36 allowed and 46 pending patents both domestically and internationally. The Company’s first cancer nanomedicine, Aurimune®, has been successfully tested in a Phase I advanced-stage cancer patient study, and Phase II testing in combination with approved chemotherapies is planned for Q2 2011. Recognizing that cancer isn’t a single disease, under Dr. Tamarkin’s leadership a pipeline of nanotherapeutics is being developed, with each product being designed to attack tumors by different mechanisms; the second-in-afamily of cancer nanomedicines, AuriTol™, is expected to enter clinical testing in 2013, with a third nanomedicine advancing through pre-clinical development. Dr. Tamarkin is also the co-inventor of the Company’s in vitro method for producing totally human monoclonal antibody therapeutics, with unique human monoclonal antibody therapeutics being developed for two clinical indications. Dr. Tamarkin was graduated from SUNY at Stony Brook receiving a B.S. degree and received his Ph.D. degree from the University of Connecticut.

Program | Tracks | Exhibition | Press | Venue | Register |
Symposia | Short Courses | News | Subscribe | Contact | Site Map
© Copyright 2010 TechConnect World. All Rights Reserved.